Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：0
作者：
Takayuki Takimoto
Tasuku Nakabori
Akio Osa
Satomu Morita
Haruko Terada
Susumu Oseto
Takashi Iwazawa
Kinya Abe
机构：
[1] Toyonaka Municipal Hospital,Department of Internal Medicine
[2] Toyonaka Municipal Hospital,Department of Surgery
来源：
International Journal of Clinical Oncology | 2012年 / 17卷
关键词：
Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; β; -Microglobulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.
引用
收藏
页码：395 / 398
页数：3
相关论文
共 52 条
  • [1] Launay-Vacher V(2009)Lung cancer and renal insufficiency: prevalence and anticancer drug issues Lung 187 69-74
  • [2] Etessami R(1995)Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function Cancer Treat Rev 21 33-64
  • [3] Janus N(2009)Chemotherapy-associated renal dysfunction Nat Rev Nephrol 5 450-462
  • [4] Kintzel PE(2006)Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) J Clin Oncol 24 3657-3663
  • [5] Dorr RT(2007)Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: meta-analysis of seven randomized clinical trials J Thorac Oncol 2 939-946
  • [6] Sahni V(1993)Phase I and pharmacokinetics study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion Cancer Res 53 1037-1042
  • [7] Choudhury D(1998)Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver Pharmacogenetics 8 391-401
  • [8] Ahmed Z(2006)Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodialyzed patient Chemotherapy 52 147-150
  • [9] Kudoh S(1980)Comparison of methods of evaluating nephrotoxicity of cis-platinum Clin Pharmacol Ther 27 557-562
  • [10] Takeda K(1989)Cisplatin nephrotoxicity Cancer Chemother Pharmacol 25 1-9
123456